Samsung Bioepis’ Trastuzumab Biosimilar Is Third Cleared By FDA – But The Market Hasn’t Formed Yet
Executive Summary
Sued by Herceptin sponsor Genentech for patent infringement, Samsung Bioepis has legal hurdles to navigate before it can roll out its trastuzumab biosimilar in the US, which has just become the third biosimilar of the cancer treatment greenlit by the FDA.
You may also be interested in...
Samsung Bioepis Gets Higher Strength Trastuzumab Nod
Although Merck has not yet debuted the Ontruzant version of trastuzumab developed by Samsung Bioepis in the US, the firm can now look to introduce two strengths of the Herceptin biosimilar, ahead of plans to spin off its biosimilar assets into a new company next year.
US Trastuzumab Competition Heats Up
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.
Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: